Comments on: Gilead’s patent for Tamiflu / oseltamivir anti-influenza drug rejected by Indian patent Office http://www.dancewithshadows.com/pillscribe/gileads-patent-for-tamiflu-oseltamivir-anti-influenza-drug-rejected-by-indian-patent-office/ The best of pharma news and views Thu, 25 Feb 2010 13:22:53 +0000 http://wordpress.org/?v=2.9.2 hourly 1 By: Gilead adefovir (Hespera) & Roche’s erlotinib (Tarceva) salts patents rejected by India's patent office | DWS Pill Scribe http://www.dancewithshadows.com/pillscribe/gileads-patent-for-tamiflu-oseltamivir-anti-influenza-drug-rejected-by-indian-patent-office/comment-page-1/#comment-138 Gilead adefovir (Hespera) & Roche’s erlotinib (Tarceva) salts patents rejected by India's patent office | DWS Pill Scribe Wed, 29 Apr 2009 11:38:49 +0000 http://www.dancewithshadows.com/pillscribe/?p=170#comment-138 [...] Adefovir dipivoxil is the patented product of Gilead. Adefovir dipivoxil is a diester prodrug of adefovir marketed by Gilead marketed under the brand name Hepsera to treat human hepatitis B virus. Related story: Gilead patent for oseltamivir (Tamiflu) rejected by Indian Patent Office [...] [...] Adefovir dipivoxil is the patented product of Gilead. Adefovir dipivoxil is a diester prodrug of adefovir marketed by Gilead marketed under the brand name Hepsera to treat human hepatitis B virus. Related story: Gilead patent for oseltamivir (Tamiflu) rejected by Indian Patent Office [...]

]]>